| 16.22 3.22 (24.77%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.44 |
1-year : | 25.04 |
| Resists | First : | 18.36 |
Second : | 21.44 |
| Pivot price | 13.82 |
|||
| Supports | First : | 14.78 |
Second : | 12.58 |
| MAs | MA(5) : | 13.66 |
MA(20) : | 13.99 |
| MA(100) : | 18  |
MA(250) : | 13.7 |
|
| MACD | MACD : | -0.9 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 40.2 |
D(3) : | 21.7 |
| RSI | RSI(14): 58.8 |
|||
| 52-week | High : | 42.11 | Low : | 3.65 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ APLM ] has closed Bollinger Bands are 15.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.47 - 16.59 | 16.59 - 16.68 |
| Low: | 13.14 - 13.24 | 13.24 - 13.32 |
| Close: | 16.06 - 16.25 | 16.25 - 16.4 |
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Mon, 27 Apr 2026
Apollomics (Nasdaq: APLM) slashes 2025 loss amid cost cuts and new vebreltinib deal revenue - Stock Titan
Mon, 27 Apr 2026
Over 282 subjects enrolled as Apollomics targets 2027 U.S. filing - Stock Titan
Mon, 27 Apr 2026
How Apollomics Inc. (APLM) Affects Rotational Strategy Timing - Stock Traders Daily
Fri, 24 Apr 2026
APLM Price Today: Apollomics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Tue, 21 Apr 2026
APLM SEC Filings - APOLLOMICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 17 Apr 2026
Apollomics (APLM) CFO has shares withheld for RSU tax obligations - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 106.1 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | -26.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4 |
| Profit Margin | 0 % |
| Operating Margin | -124.9 % |
| Return on Assets (ttm) | -72.3 % |
| Return on Equity (ttm) | -380.2 % |
| Qtrly Rev. Growth | 380.7 % |
| Gross Profit (p.s.) | 3.22 |
| Sales Per Share | 3.22 |
| EBITDA (p.s.) | -12.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.61 |
| PEG Ratio | 0 |
| Price to Book value | -4.07 |
| Price to Sales | 5.03 |
| Price to Cash Flow | -1.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|